Feili Chen

432 total citations
19 papers, 275 citations indexed

About

Feili Chen is a scholar working on Pathology and Forensic Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Feili Chen has authored 19 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 6 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Feili Chen's work include Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (4 papers) and Cancer Genomics and Diagnostics (4 papers). Feili Chen is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (4 papers) and Cancer Genomics and Diagnostics (4 papers). Feili Chen collaborates with scholars based in China, United Kingdom and Montenegro. Feili Chen's co-authors include Bing Xu, Weiguang Wang, Wenyu Li, Ling Huang, Sichu Liu, Jie Zha, Xinmiao Jiang, Huijuan Dong, Pengcheng Shi and Rongwei Li and has published in prestigious journals such as Blood, Journal of Translational Medicine and Blood Cells Molecules and Diseases.

In The Last Decade

Feili Chen

19 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feili Chen China 9 102 100 60 52 51 19 275
Rebecca Valentin United States 5 105 1.0× 99 1.0× 71 1.2× 59 1.1× 29 0.6× 12 248
Ulrike Seitz Germany 9 78 0.8× 85 0.8× 105 1.8× 56 1.1× 56 1.1× 10 512
Beatriz Sánchez-Vega Spain 12 78 0.8× 47 0.5× 93 1.6× 83 1.6× 28 0.5× 18 421
Lara M. Munín Sánchez Spain 10 80 0.8× 75 0.8× 173 2.9× 30 0.6× 12 0.2× 17 302
Nundia Louis United States 8 149 1.5× 38 0.4× 44 0.7× 31 0.6× 24 0.5× 16 267
Xiangjie Lin China 11 213 2.1× 32 0.3× 70 1.2× 58 1.1× 8 0.2× 31 396
Linh T. Nguyen United States 7 192 1.9× 33 0.3× 76 1.3× 44 0.8× 15 0.3× 17 275
Bernhard Hauns Germany 10 212 2.1× 138 1.4× 115 1.9× 132 2.5× 21 0.4× 21 429
Valeria Di Maio Italy 12 96 0.9× 103 1.0× 53 0.9× 127 2.4× 6 0.1× 26 302
Manman Deng China 15 342 3.4× 80 0.8× 141 2.4× 49 0.9× 16 0.3× 42 556

Countries citing papers authored by Feili Chen

Since Specialization
Citations

This map shows the geographic impact of Feili Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feili Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feili Chen more than expected).

Fields of papers citing papers by Feili Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feili Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feili Chen. The network helps show where Feili Chen may publish in the future.

Co-authorship network of co-authors of Feili Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Feili Chen. A scholar is included among the top collaborators of Feili Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feili Chen. Feili Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Wang, Ning, Lu Pan, Minhua Zhou, et al.. (2023). Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma. Targeted Oncology. 18(6). 941–952. 8 indexed citations
2.
Chen, Cunte, Ling Huang, Zheng Chen, et al.. (2023). Higher 13‐Gene‐Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T‐Cell Lymphoma Patients. Advanced Biology. 7(12). e2300042–e2300042. 4 indexed citations
3.
Chen, Cunte, Ling Huang, Sichu Liu, et al.. (2023). T‐cell lymphoma patient harboring BCL11B mutations had favorable overall survival. Asia-Pacific Journal of Clinical Oncology. 20(1). 81–86. 2 indexed citations
4.
Chen, Cunte, Sichu Liu, Xinmiao Jiang, et al.. (2021). Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma. Experimental Hematology and Oncology. 10(1). 20–20. 29 indexed citations
5.
Chen, Feili, Xinmiao Jiang, Sichu Liu, et al.. (2020). <p>Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population</p>. Cancer Management and Research. Volume 12. 3003–3012. 14 indexed citations
6.
Chen, Feili, Qiuxiang Ou, Xue Wu, et al.. (2020). Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use. Cancer Medicine. 9(22). 8676–8684. 40 indexed citations
7.
Jiang, Xinmiao, Ling Huang, Yan Teng, et al.. (2020). Ctdna Monitoring in Predicting Relapse of Primary Mediastinal B-Cell Lymphoma. Blood. 136(Supplement 1). 36–36. 7 indexed citations
8.
Huang, Ling, et al.. (2020). Combining the mTOR Inhibitor Everolimus and Gemcitabine in Relapsed/Refractory Peripheral T-Cell Lymphomas. Blood. 136(Supplement 1). 31–32. 1 indexed citations
9.
Chen, Feili, Xinmiao Jiang, Sichu Liu, et al.. (2019). Unusual Relapse of Primary Central Nervous System Lymphoma Both Inside and Outside Central Nervous System in Patient with Ventriculoperitoneal Shunt. World Neurosurgery. 127. 625–628. 2 indexed citations
10.
Huang, Ling, et al.. (2019). TRAF1-ALK Fusion Predicts Poor Prognosis for ALK Positive Anaplastic Large Cell Lymphoma Patients with Chemotherapy and ALK Inhibitor. Blood. 134(Supplement_1). 5224–5224. 1 indexed citations
11.
Chen, Feili, Yanwen Li, Xinmiao Jiang, et al.. (2018). Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population. World Neurosurgery. 123. e15–e24. 10 indexed citations
12.
Huang, Ling, Fen Zhang, Sichu Liu, et al.. (2017). ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population. Annals of Hematology. 97(1). 149–159. 2 indexed citations
13.
Guo, Xutao, Pengcheng Shi, Feili Chen, et al.. (2014). Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome. Blood Cells Molecules and Diseases. 53(3). 144–148. 12 indexed citations
14.
Zha, Jie, Feili Chen, Huijuan Dong, et al.. (2014). Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. Journal of Translational Medicine. 12(1). 163–163. 89 indexed citations
15.
Chen, Feili, Yuejian Liu, Shiyun Wang, et al.. (2013). Triptolide, a Chinese Herbal Extract, Enhances Drug Sensitivity of Resistant Myeloid Leukemia Cell Lines Through Downregulation of HIF-1α and Nrf2. Pharmacogenomics. 14(11). 1305–1317. 37 indexed citations
16.
17.
Shi, Pengcheng, Jie Zha, Xutao Guo, et al.. (2012). Idarubicin is Superior to Daunorubicin in Remission Induction of De Novo Acute Myeloid Leukemia Patients with High MDR1 Expression. Pharmacogenomics. 14(1). 17–23. 8 indexed citations
18.
Chen, Feili & Eric Chang. (2001). A new dynamic HMM model for speech recognition. 2769–2772. 5 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Valentin Breakdown of academic impact, for papers by Ulrike Seitz Breakdown of academic impact, for papers by Beatriz Sánchez-Vega Breakdown of academic impact, for papers by Lara M. Munín Sánchez Breakdown of academic impact, for papers by Nundia Louis Breakdown of academic impact, for papers by Xiangjie Lin Breakdown of academic impact, for papers by Linh T. Nguyen Breakdown of academic impact, for papers by Bernhard Hauns Breakdown of academic impact, for papers by Valeria Di Maio Breakdown of academic impact, for papers by Manman Deng
Rankless by CCL
2026